We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
-2.91%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$30M
Cap. Flow
-$21.6M
Cap. Flow %
-15.92%
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45

Top Buys

Rank Stock Value
1
ENOV icon
Enovis
ENOV
+$1.04M
2
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$1.04M
3
QQQ icon
Invesco QQQ Trust
QQQ
+$958K
4
QQQM icon
Invesco NASDAQ 100 ETF
QQQM
+$955K
5
SRPT icon
Sarepta Therapeutics
SRPT
+$929K

Top Sells

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$2.16M
2
CORT icon
Corcept Therapeutics
CORT
+$2.14M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$2.13M
4
KALV
KalVista Pharmaceuticals
KALV
+$1.49M
5
CATX icon
Perspective Therapeutics
CATX
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 60.25%
2 Real Estate 12.98%
3 Financials 6.42%
4 Industrials 2.59%
5 Technology 2.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$22.7B
$4.62M 3.4%
14,500
-1,500
-9% -$397K
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.36B
$4.17M 3.07%
675,000
– –
RITM icon
3
Rithm Capital
RITM
$5.2B
$4.16M 3.06%
380,966
-40,000
-10% -$443K
PFE icon
4
Pfizer
PFE
$143B
$3.92M 2.88%
140,000
-35,000
-20% -$964K
HRMY icon
5
Harmony Biosciences
HRMY
$1.96B
$3.68M 2.71%
122,000
– –
PCRX icon
6
Pacira BioSciences
PCRX
$1.01B
$3.36M 2.48%
117,500
– –
ARGX icon
7
argenx
ARGX
$53.8B
$3.12M 2.3%
7,250
-750
-9% -$287K
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$2.69M 1.98%
108,500
+3,500
+3% +$99.3K
MTG icon
9
MGIC Investment
MTG
$6.23B
$2.46M 1.82%
114,379
– –
EFC
10
Ellington Financial
EFC
$1.7B
$2.44M 1.79%
201,602
-20,000
-9% -$236K
MIRM icon
11
Mirum Pharmaceuticals
MIRM
$7.25B
$2.19M 1.61%
64,000
-30,000
-32% -$787K
DX
12
Dynex Capital
DX
$2.87B
$2.17M 1.6%
181,492
– –
ONC
13
BeOne Medicines Ltd
ONC
$32.4B
$2.14M 1.58%
15,000
-1,750
-10% -$270K
QURE icon
14
uniQure
QURE
$2.77B
$2.06M 1.52%
460,000
– –
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
$2.01M 1.48%
202,500
+27,500
+16% +$282K
DCGO icon
16
DocGo
DCGO
$64.3M
$2.01M 1.48%
650,000
– –
RWT
17
Redwood Trust
RWT
$641M
$1.87M 1.38%
288,343
– –
MFA
18
MFA Financial
MFA
$960M
$1.78M 1.31%
167,725
– –
CLDX icon
19
Celldex Therapeutics
CLDX
$2.77B
$1.76M 1.29%
47,500
+9,000
+23% +$340K
CERE
20
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.74M 1.28%
42,500
– –
CHRS icon
21
Coherus Oncology
CHRS
$216M
$1.73M 1.27%
1,000,000
– –
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$4.38B
$1.63M 1.2%
100,000
+55,000
+122% +$888K
AVBP icon
23
ArriVent BioPharma
AVBP
$1.55B
$1.6M 1.17%
86,000
+3,000
+4% +$53.5K
RPRX icon
24
Royalty Pharma
RPRX
$25.8B
$1.58M 1.17%
60,000
– –
QQQ icon
25
Invesco QQQ Trust
QQQ
$466B
$1.56M 1.15%
3,257
+2,129
+189% +$958K
1
2 3 4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, AlphaCentric Advisors held 262 positions worth $136M, down 18% from $166M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

AlphaCentric Advisors withdrew a net $21.6M in Q2 2024, closing 45 positions and reducing 87 holdings. Its most notable exit was UroGen Pharma, an estimated $2.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Enovis worth $904K.

  • AlphaCentric Advisors's largest Q2 2024 buy was Enovis: 20,000 shares worth $904K.
  • AlphaCentric Advisors added most to Invesco QQQ Trust in Q2 2024, an estimated $958K increase.
  • AlphaCentric Advisors's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $2.13M.
  • AlphaCentric Advisors fully exited UroGen Pharma in Q2 2024, selling an estimated $2.16M.
  • AlphaCentric Advisors's ten largest holdings make up 25% of its $136M portfolio in Q2 2024.
  • AlphaCentric Advisors opened 34 new positions and closed 45 in Q2 2024.
  • AlphaCentric Advisors's portfolio value fell 18% quarter-over-quarter to $136M.

Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.